XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts with Customers
9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers

3.   Revenue from Contracts with Customers. We recognize revenue when a customer obtains control of promised goods. The amount of revenue recognized reflects the consideration we expect to receive in exchange for these goods. Our revenue recognition policies have not changed from those disclosed in Note 1 to our consolidated financial statements in Item 8 of the Annual Report on Form 10-K.

Disaggregation of Revenue

The disaggregation of revenue is based on reporting segment, product category and geographical region. Beginning in the first quarter of 2020, we revised our product categories to more clearly reflect how we sell our products to our customers. We presented historical information under the new revised product categories in a Current Report on Form 8-K, filed with the SEC on April 3, 2020.

We design, develop, manufacture and market medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and OEM. Within these product categories, we sell a variety of products, including cardiology and radiology devices (which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases), as well as embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer

localization and guidance, biopsy, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.

The following tables present revenue from contracts with customers by reporting segment, product category and geographical region for the three and nine-month periods ended September 30, 2020 and 2019 (in thousands):

Three Months Ended

Three Months Ended

September 30, 2020

September 30, 2019

    

United States

    

International

    

Total

    

United States

    

International

    

Total

Cardiovascular

 

  

 

 

  

 

  

 

  

 

  

Peripheral Intervention

$

55,014

$

31,764

$

86,778

$

55,587

$

28,678

$

84,265

Cardiac Intervention

 

28,661

40,428

 

69,089

 

29,657

 

45,202

 

74,859

Custom Procedural Solutions

 

32,048

24,381

 

56,429

 

24,906

 

21,352

 

46,258

OEM

 

20,293

3,824

 

24,117

 

25,521

 

3,523

 

29,044

Total

 

136,016

100,397

 

236,413

 

135,671

 

98,755

 

234,426

 

Endoscopy

Endoscopy devices

 

7,093

 

469

 

7,562

 

8,340

 

283

 

8,623

Total

$

143,109

$

100,866

$

243,975

$

144,011

$

99,038

$

243,049

Nine Months Ended

Nine Months Ended

September 30, 2020

September 30, 2019

    

United States

    

International

    

Total

    

United States

    

International

    

Total

Cardiovascular

 

 

 

  

 

  

 

  

 

  

Peripheral Intervention

$

153,431

$

93,057

$

246,488

$

167,158

$

90,586

$

257,744

Cardiac Intervention

 

79,954

127,731

 

207,685

 

85,817

 

141,225

 

227,042

Custom Procedural Solutions

 

80,845

68,524

 

149,369

 

73,871

 

65,464

 

139,335

OEM

 

67,566

13,026

 

80,592

 

75,425

 

12,024

 

87,449

Total

 

381,796

302,338

 

684,134

 

402,271

 

309,299

 

711,570

 

Endoscopy

Endoscopy devices

 

20,509

 

1,228

 

21,737

 

24,459

 

901

 

25,360

Total

$

402,305

$

303,566

$

705,871

$

426,730

$

310,200

$

736,930